CD274 and colorectal carcinoma: To date, several clinical trials are currently investigating the clinical benefit of different anti-PD-L1 (durvalumab/avelumab) in POLE-mutated or dMMR/MSI-H CRC patients in advanced (NCT03435107, NCT03150706) [58,59] and early stage patients (NCT03827044) [60].